VIVUS Reports Second Quarter 2015 Financial Results

Go back to VIVUS Reports Second Quarter 2015 Financial Results

Vivus (VVUS) PT Cut to $4 at RBC Capital on Disappointing Results, Deep Cost Cuts; Keeps 'Outperform'

July 31, 2015 8:37 AM EDT

RBC Capital analyst Simos Simeonidis lowered his price target on Vivus (NASDAQ: VVUS) to $4.00 (from $6.00) but maintained his Outperform rating following Q2 results.

Simeonidis notes, "With Qsymia 2Q15 revenue at just $14M, Vivus is trying to preserve cash. It has announced further cost cutting,... More

VIVUS (VVUS) Tops Q2 EPS by 5c

July 30, 2015 4:01 PM EDT

VIVUS (NASDAQ: VVUS) reported Q2 EPS of ($0.19), $0.05 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $23 million versus the consensus estimate of $18.76 million.

"The U.S. market for branded anti-obesity pharmacotherapeutics has developed at a substantially lower rate than expected, held in check by a number of factors," said Seth H. Z. Fischer, CEO. "As stated previously, we have watched this trend closely... More